Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator

  • Nonell, Santi
  • Bresolí-Obach, Roger
  • Font Inglès, Joan
  • López-Cano, Marc
  • Notartomaso, Serena
  • Scarselli, Pamela
  • Di Pietro, Paola
  • Battaglia, Giuseppe
  • Malhaire, Fanny
  • Rovira, Xavier
  • Catena, Juanlo
  • Giraldo, Jesús
  • Pin, Jean-Philippe
  • Fernández-Dueñas, Víctor
  • Goudet, Cyril
  • Nicoletti, Ferdinando
  • Llebaria, Amadeu
  • Ciruela, Francisco
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu5) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug’s release, which effectively controls mGlu5 receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu5 receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator

  • Nonell, Santi
  • Bresolí-Obach, Roger
  • Font Inglès, Joan
  • López-Cano, Marc
  • Notartomaso, Serena
  • Scarselli, Pamela
  • Di Pietro, Paola
  • Battaglia, Giuseppe
  • Malhaire, Fanny
  • Rovira, Xavier
  • Catena, Juanlo
  • Giraldo, Jesús
  • Pin, Jean-Philippe
  • Fernández-Dueñas, Víctor
  • Goudet, Cyril
  • Nicoletti, Ferdinando
  • Llebaria, Amadeu
  • Ciruela, Francisco
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu5) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug’s release, which effectively controls mGlu5 receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu5 receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Shining Light On An mGlu5 Photoswitchable NAM, A Theoretical Perspective

  • Dalton, James A. R.|||0000-0002-5279-4581
  • Lans, Isaias|||0000-0002-9298-0346
  • Rovira Algans, Xavier
  • Malhaire, Fanny
  • Gómez-Santacana, Xavier|||0000-0001-8830-0494
  • Pittolo, Silvia|||0000-0002-5673-1692
  • Gorostiza, Pau|||0000-0002-7268-5577
  • Llebaria, Amadeu|||0000-0002-8200-4827
  • Goudet, Cyril|||0000-0002-8255-3535
  • Pin, Jean-Philippe|||0000-0002-1423-345X
  • Giraldo, Jesús|||0000-0001-7082-4695
Metabotropic glutamate receptors (mGluRs) are important drug targets because of their involvement in several neurological diseases. Among mGluRs, mGlu5 is a particularly high-profile target because its positive or negative allosteric modulation can potentially treat schizophrenia or anxiety and chronic pain, respectively. Here, we computationally and experimentally probe the functional binding of a novel photoswitchable mGlu5 NAM, termed alloswitch-1, which loses its NAM functionality under violet light. We show alloswitch-1 binds deep in the allosteric pocket in a similar fashion to mavoglurant, the co-crystallized NAM in the mGlu5 transmembrane domain crystal structure. Alloswitch-1, like NAM 2-Methyl-6-(phenylethynyl)pyridine (MPEP), is significantly affected by P655M mutation deep in the allosteric pocket, eradicating its functionality. In MD simulations, we show alloswitch-1 and MPEP stabilize the co-crystallized water molecule located at the bottom of the allosteric site that is seemingly characteristic of the inactive receptor state. Furthermore, both NAMs form H-bonds with S809 on helix 7, which may constitute an important stabilizing interaction for NAM-induced mGlu5 inactivation. Alloswitch-1, through isomerization of its amide group from trans to cis is able to form an additional interaction with N747 on helix 5. This may be an important interaction for amide-containing mGlu5 NAMs, helping to stabilize their binding in a potentially unusual cis-amide state. Simulated conformational switching of alloswitch-1 in silico suggests photoisomerization of its azo group from trans to cis may be possible within the allosteric pocket. However, photoexcited alloswitch-1 binds in an unstable fashion, breaking H-bonds with the protein and destabilizing the co-crystallized water molecule. This suggests photoswitching may have destabilizing effects on mGlu5 binding and functionality.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Angiotensin II type 1/adenosine A receptor oligomers, a novel target for tardive dyskinesia

  • Oliveira, Paulo A. de|||0000-0002-0852-4920
  • Dalton, James A. R.|||0000-0002-5279-4581
  • López Cano, Marc|||0000-0001-8885-3726
  • Ricarte, Adrià
  • Morató, Xavier|||0000-0002-3012-2864
  • Matheus, Filipe C.
  • Cunha, Andréia S.
  • Müller, Christa E.
  • Takahashi, Reinaldo N.
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Prediger, Rui D.
  • Ciruela, Francisco|||0000-0003-0832-3739
Tardive dyskinesia (TD) is a serious motor side effect that may appear after long-term treatment with neuroleptics and mostly mediated by dopamine D receptors (DRs). Striatal DR functioning may be finely regulated by either adenosine A receptor (AR) or angiotensin receptor type 1 (ATR) through putative receptor heteromers. Here, we examined whether AR and ATR may oligomerize in the striatum to synergistically modulate dopaminergic transmission. First, by using bioluminescence resonance energy transfer, we demonstrated a physical ATR-AR interaction in cultured cells. Interestingly, by protein-protein docking and molecular dynamics simulations, we described that a stable heterotetrameric interaction may exist between ATR and AR bound to antagonists (i.e. losartan and istradefylline, respectively). Accordingly, we subsequently ascertained the existence of ATR/AR heteromers in the striatum by proximity ligation in situ assay. Finally, we took advantage of a TD animal model, namely the reserpine-induced vacuous chewing movement (VCM), to evaluate a novel multimodal pharmacological TD treatment approach based on targeting the ATR/AR complex. Thus, reserpinized mice were co-treated with sub-effective losartan and istradefylline doses, which prompted a synergistic reduction in VCM. Overall, our results demonstrated the existence of striatal ATR/AR oligomers with potential usefulness for the therapeutic management of TD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacological evidence for a metabotropic glutamate receptor heterodimer in neuronal cells

  • Moreno Delgado, David|||0000-0003-0070-2566
  • Møller, Thor C.|||0000-0002-2256-577X
  • Ster, Jeanne
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Maurel, Damien
  • Rovira, Xavier|||0000-0002-9764-9927
  • Scholler, Pauline
  • Zwier, Jurriaan M.|||0000-0001-9017-5856
  • Perroy, Julie
  • Durroux, Thierry
  • Trinquet, Eric
  • Prezeau, Laurent
  • Rondard, Philippe|||0000-0003-1134-2738
  • Pin, Jean-Philippe|||0000-0002-1423-345X
Metabotropic glutamate receptors (mGluRs) are mandatory dimers playing important roles in regulating CNS function. Although assumed to form exclusive homodimers, 16 possible heterodimeric mGluRs have been proposed but their existence in native cells remains elusive. Here, we set up two assays to specifically identify the pharmacological properties of rat mGlu heterodimers composed of mGlu2 and 4 subunits. We used either a heterodimer-specific conformational LRET-based biosensor or a system that guarantees the cell surface targeting of the heterodimer only. We identified mGlu2-4 specific pharmacological fingerprints that were also observed in a neuronal cell line and in lateral perforant path terminals naturally expressing mGlu2 and mGlu4. These results bring strong evidence for the existence of mGlu2-4 heterodimers in native cells. In addition to reporting a general approach to characterize heterodimeric mGluRs, our study opens new avenues to understanding the pathophysiological roles of mGlu heterodimers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Analysis of positive and negative allosteric modulation in metabotropic glutamate receptors 4 and 5 with a dual ligand

  • Dalton, James A. R.|||0000-0002-5279-4581
  • Pin, Jean-Philippe|||0000-0002-1423-345X
  • Giraldo, Jesús|||0000-0001-7082-4695
As class C GPCRs and regulators of synaptic activity, human metabotropic glutamate receptors (mGluRs) 4 and 5 are prime targets for allosteric modulation, with mGlu5 inhibition or mGlu4 stimulation potentially treating conditions like chronic pain and Parkinson's disease. As an allosteric modulator that can bind both receptors, 2-Methyl-6-(phenylethynyl)pyridine (MPEP) is able to negatively modulate mGlu5 or positively modulate mGlu4. At a structural level, how it elicits these responses and how mGluRs undergo activation is unclear. Here, we employ homology modelling and 30 µs of atomistic molecular dynamics (MD) simulations to probe allosteric conformational change in mGlu4 and mGlu5, with and without docked MPEP. Our results identify several structural differences between mGlu4 and mGlu5, as well as key differences responsible for MPEP-mediated positive and negative allosteric modulation, respectively. A novel mechanism of mGlu4 activation is revealed, which may apply to all mGluRs in general. This involves conformational changes in TM3, TM4 and TM5, separation of intracellular loop 2 (ICL2) from ICL1/ICL3, and destabilization of the ionic-lock. On the other hand, mGlu5 experiences little disturbance when MPEP binds, maintaining its inactive state with reduced conformational fluctuation. In addition, when MPEP is absent, a lipid molecule can enter the mGlu5 allosteric pocket.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Complementary Scale of Biased Agonism for Agonists with Differing Maximal Responses

  • Burgueño, Javier
  • Pujol Argemí, Marta
  • Monroy, Xavier
  • Roche, David
  • Varela, Maria Jose
  • Merlos, Manuel
  • Giraldo, Jesús|||0000-0001-7082-4695
Compelling data in the literature from the recent years leave no doubt about the pluridimensional nature of G protein-coupled receptor function and the fact that some ligands can couple with different efficacies to the multiple pathways that a receptor can signal through, a phenomenon most commonly known as functional selectivity or biased agonism. Nowadays, transduction coefficients (log(τ/K)), based on the Black and Leff operational model of agonism, are widely used to calculate bias. Nevertheless, combining both affinity and efficacy in a single parameter can result in compounds showing a defined calculated bias of one pathway over other though displaying varying experimental bias preferences. In this paper, we present a novel scale (log(τ)), that attempts to give extra substance to different compound profiles in order to better classify compounds and quantify their bias. The efficacy-driven log(τ) scale is not proposed as an alternative to the affinity&efficacy-driven log(τ/K) scale but as a complement in those situations where partial agonism is present. Both theoretical and practical approaches using μ-opioid receptor agonists are presented.